BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects

Overview of attention for article published in Frontiers in immunology, July 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 38 Dimensions

Readers on

mendeley: 55 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 38 publications that cite this research output.

38

The most recent citing publications are shown below. View all 38 publications that cite this research output on Dimensions.

Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents

Article in Cancers (May 2024)

The impact of Bruton’s tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia

Article in Frontiers in Oncology (May 2024)

Multi-center study of COVID-19 infection in elderly patients with lymphoma: on behalf of Jiangsu Cooperative Lymphoma Group (JCLG)

Article in Annals of Hematology (April 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.